Domestic obesity drug-related stocks showed overall weakness during trading on the 2nd. As U.S. semiconductor stocks struggled and major Korean semiconductor stocks such as Samsung Electronics and SK Hynix declined on the same day, both the KOSPI and KOSDAQ fell together, leading to profit-taking sell-offs in the pharmaceutical and biotech sectors, which have a high proportion of growth stocks.

As of the afternoon, major stock prices are as follows. Peptron is trading at 177,700 won, down 4,000 won (2.20%) from the previous trading day. Nature Cell widened its loss, dropping 1,550 won (6.70%) to 21,600 won, and Hyundai Pharm also recorded 5,180 won, down 420 won (7.50%). YuYu Pharma fell 60 won (1.56%) to 3,780 won, and Myungmoon Pharm traded at 1,278 won, down 4 won (0.31%), failing to escape the bearish trend.

In the obesity drug market, a core growth area for the global pharmaceutical industry, competition is fierce to develop long-acting treatments and new candidate substances. Accordingly, market attention remains high on the research and development (R&D) capabilities and technological competitiveness of related domestic companies.

Stock market experts analyzed that the corporate value of obesity drug-related companies will be significantly influenced by new drug development outcomes, clinical trial progress, and the success of technology transfers. However, they advised that in the short term, the price fluctuation range of related stocks could also expand due to overall market volatility and shrinking investor sentiment.

[※ This article was written with AI assistance. This article is not an investment solicitation, and the final judgment and responsibility for investments lie with the investor.]